ALKS Nov 2024 27.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:37PM EDT. Market open.
| Previous close | 4.1700 |
| Open | 4.2100 |
| Bid | 2.4500 |
| Ask | 4.4000 |
| Strike | 27.00 |
| Expiry date | 2024-11-15 |
| Day's range | 4.1700 - 4.2100 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
PR NewswireAlkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. The data are being presented at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston.
ZacksWhy Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investor's Business DailyThe Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.
© 2024 Yahoo. All rights reserved.